{# ── Billing problem banner: payment failed (past_due) or retries exhausted (unpaid). Pro access is gated off by is_pro until the card is fixed, so prompt the user to update billing. ── #}
NASDAQ: OTLK Outlook Therapeutics, Inc. 8-K

Outlook Therapeutics wins FDA appeal, confirms LYTENAVA effectiveness for eye disease

Filed May 26, 2026 · Period ending May 26, 2026 · ~1 min read

3 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade OTLK commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Feedback
View original filing on SEC.gov

Generated by AI · May 27, 2026 4:41 PM